# Pediatric Asthma Management

## Diagnosis
- Recurrent episodes of wheezing, cough, shortness of breath, and chest tightness
- Reversible airflow obstruction (>12% improvement in FEV1 post-bronchodilator in children >= 5 years)
- Spirometry recommended for children >= 5 years for diagnosis and monitoring

## Stepwise Therapy: Ages 0-4 Years

| Step | Preferred Controller | Alternative |
|---|---|---|
| Step 1 | SABA PRN only | -- |
| Step 2 | Low-dose ICS daily | Montelukast |
| Step 3 | Medium-dose ICS daily | Low-dose ICS + montelukast |
| Step 4 | Medium-dose ICS + montelukast or referral | Specialist referral |

## Stepwise Therapy: Ages 5-11 Years

| Step | Preferred Controller | Alternative |
|---|---|---|
| Step 1 | SABA PRN only | -- |
| Step 2 | Low-dose ICS daily | Montelukast, cromolyn |
| Step 3 | Low-dose ICS + LABA OR medium-dose ICS | Low-dose ICS + montelukast |
| Step 4 | Medium-dose ICS + LABA | Medium-dose ICS + montelukast |
| Step 5 | High-dose ICS + LABA | Referral for biologic therapy |
| Step 6 | High-dose ICS + LABA + oral corticosteroid | Omalizumab or other biologic |

## Stepwise Therapy: Ages >= 12 Years
- Follow adult NAEPP/GINA guidelines
- Step 1: Low-dose ICS-formoterol PRN (preferred, GINA) or SABA PRN
- Step 2: Low-dose ICS daily + SABA PRN or low-dose ICS-formoterol PRN
- Steps 3-5: Escalate ICS dose and add LABA, LAMA, biologics as needed

## ICS Dosing (Approximate Daily Doses - Fluticasone Propionate Equivalent)

| Age Group | Low Dose | Medium Dose | High Dose |
|---|---|---|---|
| 0-4 years | 88 mcg | 176 mcg | >176 mcg |
| 5-11 years | 88-176 mcg | 176-352 mcg | >352 mcg |
| >= 12 years | 100-250 mcg | 250-500 mcg | >500 mcg |

## Acute Exacerbation: PRAM Score (Preschool Respiratory Assessment Measure)

Validated for ages 1-6 years. Scored 0-12.

| Parameter | 0 | 1 | 2 | 3 |
|---|---|---|---|---|
| O2 saturation | >= 95% | 92-94% | <92% | -- |
| Suprasternal retractions | Absent | Present | -- | -- |
| Scalene retractions | Absent | Present | -- | -- |
| Air entry | Normal | Decreased at bases | Widespread decrease | Absent/minimal |
| Wheezing | Absent | Expiratory only | Inspiratory + expiratory | Audible without stethoscope or silent chest |

**Interpretation**: Mild (0-3), Moderate (4-7), Severe (8-12)

## Emergency Department Management

### Mild Exacerbation (PRAM 0-3)
- Salbutamol (albuterol) MDI 4-8 puffs via spacer every 20 minutes x 3 doses
- Reassess after each treatment cycle
- Consider oral prednisolone 1-2 mg/kg (max 40 mg) if incomplete response

### Moderate Exacerbation (PRAM 4-7)
- Salbutamol nebulization 2.5-5 mg every 20 minutes x 3 doses
- Ipratropium bromide 250-500 mcg nebulized with first 3 salbutamol treatments
- Oral prednisolone 1-2 mg/kg (max 40-60 mg) or dexamethasone 0.6 mg/kg (max 16 mg)
- Reassess after each hour of treatment

### Severe Exacerbation (PRAM 8-12)
- Continuous albuterol nebulization 10-15 mg/hour
- Ipratropium 500 mcg nebulized every 20 minutes x 3
- IV methylprednisolone 2 mg/kg bolus (max 60 mg)
- IV magnesium sulfate 50 mg/kg (max 2g) over 20 minutes for impending respiratory failure
- Consider terbutaline IV infusion if refractory
- Prepare for non-invasive ventilation or intubation if deteriorating

### Adjunct Therapies
- Supplemental oxygen to maintain SpO2 >= 92%
- Heliox (70:30 helium-oxygen) may reduce work of breathing in severe cases
- Epinephrine IM 0.01 mg/kg (max 0.5 mg) for anaphylaxis-triggered bronchospasm

## Discharge Criteria
- PRAM score <= 3 sustained for at least 1 hour after last bronchodilator
- SpO2 >= 92% on room air
- Adequate oral intake and able to ambulate (age-appropriate)
- Caregiver demonstrates proper inhaler technique with spacer
- Asthma action plan reviewed and provided

### Discharge Prescriptions
- Albuterol MDI with spacer: 2-4 puffs every 4-6 hours PRN
- Prednisolone 1 mg/kg/day for 3-5 days OR dexamethasone 0.6 mg/kg daily for 2 days
- Initiate or step up controller therapy as appropriate
- Follow-up with primary care within 1-4 weeks
